Inhibrx Biosciences, Inc.
INBX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $1 | $0 | $0 |
| % Growth | -100% | – | -100% | – |
| Cost of Goods Sold | $1 | $1 | $1 | $1 |
| Gross Profit | -$1 | $1 | -$1 | -$1 |
| % Margin | – | 49.1% | – | -589% |
| R&D Expenses | $28 | $22 | $37 | $33 |
| G&A Expenses | $0 | $6 | $6 | $17 |
| SG&A Expenses | $5 | $6 | $6 | $17 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$1 | -$1 | -$1 |
| Operating Expenses | $33 | $28 | $42 | $49 |
| Operating Income | -$34 | -$27 | -$43 | -$50 |
| % Margin | – | -2,106.8% | – | -49,928% |
| Other Income/Exp. Net | -$1 | -$1 | -$0 | $2 |
| Pre-Tax Income | -$35 | -$29 | -$43 | -$48 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$35 | -$29 | -$43 | -$48 |
| % Margin | – | -2,204.2% | – | -47,865% |
| EPS | -2.28 | -1.85 | -2.8 | -3.31 |
| % Growth | -23.2% | 33.9% | 15.4% | – |
| EPS Diluted | -2.28 | -1.85 | -2.8 | -3.31 |
| Weighted Avg Shares Out | 15 | 15 | 15 | 14 |
| Weighted Avg Shares Out Dil | 15 | 15 | 15 | 14 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $2 | $2 | $2 |
| Interest Expense | $3 | $3 | $3 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$31 | -$25 | -$40 | -$47 |
| % Margin | – | -1,911.5% | – | -47,176% |